Changeflow GovPing Healthcare & Life Sciences Fuchs Dystrophy Descemet Polishing Clinical Tri...
Routine Notice Added Final

Fuchs Dystrophy Descemet Polishing Clinical Trial NCT07539012

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

The NIH ClinicalTrials.gov registry has posted a new clinical trial (NCT07539012) titled 'Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy.' The study will evaluate whether polishing the Descemet membrane prior to cultured endothelial cell injection improves guttae removal and cell adhesion in Fuchs dystrophy patients. Corneal endothelial keratoplasty is currently the reference treatment, but graft shortages have driven interest in cell-based therapies.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document registers a new clinical trial on ClinicalTrials.gov. The trial will assess the effectiveness of Descemet membrane polishing in removing pathological guttae and improving survival of injected cultured endothelial cells in Fuchs endothelial corneal dystrophy patients.

For healthcare providers and clinical investigators, this represents an emerging area of translational research in corneal cell-based therapy. Sponsors and researchers developing similar endothelial cell injection protocols should monitor this trial for outcomes data on polishing efficacy.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy

N/A NCT07539012 Kind: NA Apr 20, 2026

Abstract

Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It results from the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the reference treatment, but graft shortages have promoted the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and improving survival of injected cells remains uncertain. An in vivo clinical evaluation is therefore required to assess its impact on guttae removal.

Conditions: D005642

Interventions: Fuchs Polishing

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 20th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Ophthalmic surgery research Cell-based therapy development
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!